Skip to main content

Merck & Co.

Lupus Nephritis Market to Reach $4.08B by 2034, 8.5% CAGR

Lupus Nephritis Market to Reach $4.08B by 2034, 8.5% CAGR

Pune, India – September 22, 2026 -- The global lupus nephritis market was valued at $1.96 billion in 2025 and is projected to reach $4.08 billion by 2034, expanding at a compound annual growth rate of 8.5% through the forecast period, according to a new analysis by Maximize Market Research.

North America leads treatment adoption on strong pharmaceutical research capabilities

North America holds the leading position in the market, supported by advanced healthcare infrastructure and higher awareness of autoimmune diseases. The United States drives regional demand through its established pharmaceutical industry and strong clinical research activity, while Canada contributes through its developed healthcare system focused on autoimmune disease management.

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

San Rafael, Calif. – September 17, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 10, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.